These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 31762745)
1. Methimazole-Induced Leukocytoclastic Vasculitis: A Case Report. Tawanwongsri W; Chayavichitsilp P Case Rep Dermatol; 2019; 11(3):303-309. PubMed ID: 31762745 [TBL] [Abstract][Full Text] [Related]
2. Perinuclear antineutrophil cytoplasmic antibody-associated vasculitis in a patient with Graves' disease treated with methimazole. Bilu Martin D; Deng A; Gaspari A; Pearson F Skinmed; 2006; 5(6):302-5. PubMed ID: 17086001 [TBL] [Abstract][Full Text] [Related]
3. Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU). Kubota S Intern Med; 2016; 55(22):3235-3237. PubMed ID: 27853063 [TBL] [Abstract][Full Text] [Related]
4. Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves' disease. Poomthavorn P; Mahachoklertwattana P; Tapaneya-Olarn W; Chuansumrit A; Chunharas A J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1295-301. PubMed ID: 12549809 [TBL] [Abstract][Full Text] [Related]
5. The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant. Kimura M; Seki T; Ozawa H; Ishihara T; Komatsu M; Tajiri S; Yanagi H; Nishina M; Noh JY; Fukagawa M; Takagi A Endocr J; 2013; 60(3):383-8. PubMed ID: 23154533 [TBL] [Abstract][Full Text] [Related]
6. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease. Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243 [TBL] [Abstract][Full Text] [Related]
7. Antithyroid arthritis syndrome caused by methimazole in a patient with Graves' disease. Kawasumi M; Kubota M; Yoshii Y; Tokunaga T Endocrinol Diabetes Metab Case Rep; 2023 Jul; 2023(3):. PubMed ID: 37401469 [TBL] [Abstract][Full Text] [Related]
8. Leukocytoclastic vasculitis: a rare manifestation of propylthiouracil hypersensitivity. Erem C; Yucel Y; Ya Z; Reis A; Kocak M; Hacihasanoglu A Med Princ Pract; 2005; 14(5):366-9. PubMed ID: 16103706 [TBL] [Abstract][Full Text] [Related]
9. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329 [TBL] [Abstract][Full Text] [Related]
10. Acute pancreatitis induced by methimazole in a patient with Graves' disease. Yang M; Qu H; Deng HC Thyroid; 2012 Jan; 22(1):94-6. PubMed ID: 22136208 [TBL] [Abstract][Full Text] [Related]
11. Two Cases of Methimazole-Induced Agranulocytosis With Their Risk Factors. Khine A; Dhillon K; Jo L; Wormser V; Naing S; Mishra S AACE Clin Case Rep; 2022; 8(2):82-84. PubMed ID: 35415227 [TBL] [Abstract][Full Text] [Related]
13. Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment. Villagelin D; Romaldini JH; Santos RB; Milkos AB; Ward LS Thyroid; 2015 Dec; 25(12):1282-90. PubMed ID: 26414885 [TBL] [Abstract][Full Text] [Related]
14. [Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period]. Komaki T; Sakata S; Nakamura S; Matsuda M; Kojima N; Takuno H; Miura K Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):627-39. PubMed ID: 2583311 [TBL] [Abstract][Full Text] [Related]
15. Use of antihistamines after serious allergic reaction to methimazole in pediatric Graves' disease. Toderian AB; Lawson ML Pediatrics; 2014 May; 133(5):e1401-4. PubMed ID: 24777217 [TBL] [Abstract][Full Text] [Related]
16. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Takata K; Kubota S; Fukata S; Kudo T; Nishihara E; Ito M; Amino N; Miyauchi A Thyroid; 2009 Jun; 19(6):559-63. PubMed ID: 19445623 [TBL] [Abstract][Full Text] [Related]
17. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease. Bogazzi F; Bartalena L; Campomori A; Brogioni S; Traino C; De Martino F; Rossi G; Lippi F; Pinchera A; Martino E J Clin Endocrinol Metab; 2002 Oct; 87(10):4490-5. PubMed ID: 12364424 [TBL] [Abstract][Full Text] [Related]
18. A hyperthyroid patient with Graves' disease who was strongly resistant to methimazole: investigation on possible mechanisms of the resistance. Li H; Okuda J; Akamizu T; Mori T Endocr J; 1995 Oct; 42(5):697-704. PubMed ID: 8574295 [TBL] [Abstract][Full Text] [Related]
19. Annular leukocytoclastic vasculitis associated with anti-tuberculosis medications: a case report. Chanprapaph K; Roongpisuthipong W; Thadanipon K J Med Case Rep; 2013 Jan; 7():34. PubMed ID: 23369624 [TBL] [Abstract][Full Text] [Related]
20. Methimazole-induced ANCA-associated vasculitis with diffuse alveolar haemorrhage. Arai N; Nemoto K; Oh-Ishi S; Nonaka M; Hayashihara K; Saito T Respirol Case Rep; 2018 Jul; 6(5):e00315. PubMed ID: 29760925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]